Browse News
Filter News
Found 2,421 articles
-
With several key decisions still on the docket, December promises to be an exciting month for FDA watchers as 2023 comes to an end.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Alnylam to Webcast Virtual R&D Day - December 6, 2023
12/6/2023
Alnylam Pharmaceuticals, Inc. announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET.
-
Moving RNA Therapeutics Beyond the Liver
12/4/2023
From the skin to the lungs to the central nervous system, biotech companies are making progress toward delivering RNA therapeutics to multiple targets throughout the body. But challenges remain. -
Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
12/4/2023
Zenas BioPharma announced the appointment of Jennifer Fox as its Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph. D as Head of Research and Development and Chief Medical Officer.
-
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
11/30/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the “Largest Employer” category.
-
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
11/28/2023
Korro Bio, Inc. today announced the appointment of Rachel Meyers, PhD, to the Company’s Board of Directors.
-
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
11/28/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA interference (RNAi) therapeutics manufacturing landscape on Friday, December 8, 2023, at 10:00 am ET.
-
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
11/13/2023
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting ® 2023.
-
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
11/11/2023
Alnylam Pharmaceuticals, Inc. announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of patients with hypertension and high cardiovascular risk.
-
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
11/10/2023
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting ® 2023.
-
Terray Therapeutics Announces Investment from NVIDIA to Enable Generative AI Design for Drug Discovery
11/9/2023
Terray Therapeutics announced an equity investment by NVentures, NVIDIA's venture capital arm.
-
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
11/9/2023
Vistagen (Nasdaq: VTGN) today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023.
-
BioSpace has published its annual 2024 Best Places to Work list.
-
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
11/7/2023
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023.
-
BioSpace Announces 2024 Best Places to Work in Biopharma Winners
11/7/2023
BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list.
-
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/7/2023
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today reported third quarter 2023 financial results and provided a corporate update.
-
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - November 7, 2023
11/7/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences.
-
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
11/3/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.
-
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
11/2/2023
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, reported business highlights and financial results for the third quarter ended September 30, 2023.